| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer.
|
Blood
|
2005
|
7.28
|
|
2
|
Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia.
|
N Engl J Med
|
2004
|
7.10
|
|
3
|
Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy.
|
Blood
|
2004
|
7.09
|
|
4
|
Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study.
|
Lancet
|
2007
|
6.93
|
|
5
|
Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease.
|
Blood
|
2007
|
6.45
|
|
6
|
Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics.
|
Blood
|
2010
|
5.79
|
|
7
|
Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis.
|
Lancet Oncol
|
2010
|
4.67
|
|
8
|
Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood.
|
Blood
|
2010
|
4.02
|
|
9
|
Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units.
|
Blood
|
2009
|
3.62
|
|
10
|
Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning.
|
Blood
|
2003
|
3.42
|
|
11
|
Results of the Cord Blood Transplantation Study (COBLT): clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies.
|
Blood
|
2008
|
3.33
|
|
12
|
Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems.
|
Biol Blood Marrow Transplant
|
2002
|
3.29
|
|
13
|
Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: a study by the Eurocord-Netcord and lymphoma working party of the European group for blood and marrow transplantation.
|
J Clin Oncol
|
2008
|
2.74
|
|
14
|
Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival.
|
Biol Blood Marrow Transplant
|
2007
|
2.60
|
|
15
|
Acute graft-versus-host disease after unrelated donor umbilical cord blood transplantation: analysis of risk factors.
|
Blood
|
2008
|
2.53
|
|
16
|
Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: the Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry.
|
J Clin Oncol
|
2004
|
2.21
|
|
17
|
Stable gene transfer and expression in cord blood-derived CD34+ hematopoietic stem and progenitor cells by a hyperactive Sleeping Beauty transposon system.
|
Blood
|
2009
|
2.15
|
|
18
|
Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity.
|
Sci Transl Med
|
2011
|
2.14
|
|
19
|
Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation.
|
Blood
|
2006
|
2.10
|
|
20
|
Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor.
|
Blood
|
2002
|
2.03
|
|
21
|
Searching for unrelated donor hematopoietic stem cells: availability and speed of umbilical cord blood versus bone marrow.
|
Biol Blood Marrow Transplant
|
2002
|
1.89
|
|
22
|
A scheme for defining cause of death and its application in the T cell depletion trial.
|
Biol Blood Marrow Transplant
|
2007
|
1.89
|
|
23
|
Unrelated donor hematopoietic cell transplantation: marrow or umbilical cord blood?
|
Blood
|
2003
|
1.87
|
|
24
|
TALEN-based gene correction for epidermolysis bullosa.
|
Mol Ther
|
2013
|
1.84
|
|
25
|
Double umbilical cord blood transplantation.
|
Curr Opin Immunol
|
2006
|
1.81
|
|
26
|
Double unit grafts successfully extend the application of umbilical cord blood transplantation in adults with acute leukemia.
|
Blood
|
2012
|
1.81
|
|
27
|
Umbilical cord blood regulatory T-cell expansion and functional effects of tumor necrosis factor receptor family members OX40 and 4-1BB expressed on artificial antigen-presenting cells.
|
Blood
|
2008
|
1.80
|
|
28
|
Analyzing the cost effectiveness of Santiago, Chile's policy of using urban forests to improve air quality.
|
J Environ Manage
|
2007
|
1.76
|
|
29
|
Unrelated cord blood transplantation in children with sickle cell disease: review of four-center experience.
|
Pediatr Transplant
|
2007
|
1.76
|
|
30
|
Expanding the role of umbilical cord blood transplantation.
|
Br J Haematol
|
2007
|
1.67
|
|
31
|
Successful immune reconstitution decreases leukemic relapse and improves survival in recipients of unrelated cord blood transplantation.
|
Biol Blood Marrow Transplant
|
2006
|
1.65
|
|
32
|
Amelioration of epidermolysis bullosa by transfer of wild-type bone marrow cells.
|
Blood
|
2008
|
1.62
|
|
33
|
Induced pluripotent stem cells from individuals with recessive dystrophic epidermolysis bullosa.
|
J Invest Dermatol
|
2010
|
1.62
|
|
34
|
Urban forests and pollution mitigation: analyzing ecosystem services and disservices.
|
Environ Pollut
|
2011
|
1.56
|
|
35
|
Reduced-intensity conditioning transplantation in acute leukemia: the effect of source of unrelated donor stem cells on outcomes.
|
Blood
|
2012
|
1.55
|
|
36
|
Mislabeled units of umbilical cord blood detected by a quality assurance program at the transplantation center.
|
Blood
|
2009
|
1.53
|
|
37
|
The evolution of gene transfer, gene therapy, and the RAC: IOM recommendations to the NIH director.
|
Mol Ther
|
2014
|
1.53
|
|
38
|
Reduced-intensity conditioning regimens for allogeneic transplantation in children with acute lymphoblastic leukemia.
|
Biol Blood Marrow Transplant
|
2010
|
1.53
|
|
39
|
Negative effect of KIR alloreactivity in recipients of umbilical cord blood transplant depends on transplantation conditioning intensity.
|
Blood
|
2009
|
1.51
|
|
40
|
Good manufacturing practices production of natural killer cells for immunotherapy: a six-year single-institution experience.
|
Transfusion
|
2007
|
1.49
|
|
41
|
Haematopoeitic cell transplantation for Fanconi anaemia - when and how?
|
Br J Haematol
|
2010
|
1.49
|
|
42
|
Sleeping Beauty transposon-mediated engineering of human primary T cells for therapy of CD19+ lymphoid malignancies.
|
Mol Ther
|
2008
|
1.47
|
|
43
|
Results of the cord blood transplantation study (COBLT): outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with lysosomal and peroxisomal storage diseases.
|
Biol Blood Marrow Transplant
|
2006
|
1.45
|
|
44
|
Alternative haematopoietic stem cell sources for transplantation: place of umbilical cord blood.
|
Br J Haematol
|
2009
|
1.44
|
|
45
|
Serious infections after unrelated donor transplantation in 136 children: impact of stem cell source.
|
Biol Blood Marrow Transplant
|
2005
|
1.41
|
|
46
|
4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies.
|
Hum Gene Ther
|
2010
|
1.40
|
|
47
|
Chronic graft-versus-host disease (cGVHD) following unrelated donor hematopoietic stem cell transplantation (HSCT): higher response rate in recipients of unrelated donor (URD) umbilical cord blood (UCB).
|
Biol Blood Marrow Transplant
|
2007
|
1.39
|
|
48
|
Higher risk of cytomegalovirus and aspergillus infections in recipients of T cell-depleted unrelated bone marrow: analysis of infectious complications in patients treated with T cell depletion versus immunosuppressive therapy to prevent graft-versus-host disease.
|
Biol Blood Marrow Transplant
|
2007
|
1.39
|
|
49
|
Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor.
|
Biol Blood Marrow Transplant
|
2008
|
1.35
|
|
50
|
Stable long-term donor engraftment following reduced-intensity hematopoietic cell transplantation for sickle cell disease.
|
Biol Blood Marrow Transplant
|
2008
|
1.27
|
|
51
|
Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen for advanced Hodgkin lymphoma.
|
Blood
|
2005
|
1.21
|
|
52
|
Umbilical-cord blood transplantation for the treatment of cancer.
|
Nat Rev Cancer
|
2003
|
1.18
|
|
53
|
Busulfan/melphalan/antithymocyte globulin followed by unrelated donor cord blood transplantation for treatment of infant leukemia and leukemia in young children: the Cord Blood Transplantation study (COBLT) experience.
|
Biol Blood Marrow Transplant
|
2005
|
1.17
|
|
54
|
Successful hematopoietic stem cell transplantation for Fanconi anemia from an unaffected HLA-genotype-identical sibling selected using preimplantation genetic diagnosis.
|
Blood
|
2003
|
1.16
|
|
55
|
Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: analysis of graft sources and long-term outcome.
|
J Clin Oncol
|
2009
|
1.16
|
|
56
|
Impact of cytomegalovirus (CMV) reactivation after umbilical cord blood transplantation.
|
Biol Blood Marrow Transplant
|
2009
|
1.16
|
|
57
|
Hematopoietic differentiation of induced pluripotent stem cells from patients with mucopolysaccharidosis type I (Hurler syndrome).
|
Blood
|
2010
|
1.15
|
|
58
|
Conception to obtain hematopoietic stem cells.
|
Hastings Cent Rep
|
2002
|
1.13
|
|
59
|
Umbilical cord blood transplantation and banking.
|
Annu Rev Med
|
2006
|
1.13
|
|
60
|
Hematopoietic cell transplantation for children with acute lymphoblastic leukemia in second complete remission: similar outcomes in recipients of unrelated marrow and umbilical cord blood versus marrow from HLA matched sibling donors.
|
Biol Blood Marrow Transplant
|
2009
|
1.10
|
|
61
|
Mouse fetal and embryonic liver cells differentiate human umbilical cord blood progenitors into CD56-negative natural killer cell precursors in the absence of interleukin-15.
|
Exp Hematol
|
2008
|
1.09
|
|
62
|
Allogeneic hematopoietic stem cell transplantation in adult acute lymphocytic leukemia: impact of donor source on survival.
|
Biol Blood Marrow Transplant
|
2008
|
1.08
|
|
63
|
Antigen-specific T-lymphocyte function after cord blood transplantation.
|
Biol Blood Marrow Transplant
|
2006
|
1.08
|
|
64
|
Monitoring and preemptive rituximab therapy for Epstein-Barr virus reactivation after antithymocyte globulin containing nonmyeloablative conditioning for umbilical cord blood transplantation.
|
Biol Blood Marrow Transplant
|
2009
|
1.07
|
|
65
|
Anti-HLA antibodies in double umbilical cord blood transplantation.
|
Biol Blood Marrow Transplant
|
2011
|
1.06
|
|
66
|
Lymphodepletion followed by donor lymphocyte infusion (DLI) causes significantly more acute graft-versus-host disease than DLI alone.
|
Blood
|
2007
|
1.06
|
|
67
|
Comparable long-term survival after unrelated and HLA-matched sibling donor hematopoietic stem cell transplantations for acute leukemia in children younger than 18 months.
|
J Clin Oncol
|
2006
|
1.06
|
|
68
|
Does the hematopoietic cell transplantation specific comorbidity index predict transplant outcomes? A validation study in a large cohort of umbilical cord blood and matched related donor transplants.
|
Biol Blood Marrow Transplant
|
2008
|
1.05
|
|
69
|
First report of donor cell-derived acute leukemia as a complication of umbilical cord blood transplantation.
|
Blood
|
2005
|
1.04
|
|
70
|
Successful engraftment without radiation after fludarabine-based regimen in Fanconi anemia patients undergoing genotypically identical donor hematopoietic cell transplantation.
|
Pediatr Blood Cancer
|
2006
|
1.04
|
|
71
|
Costs of pediatric allogeneic hematopoietic-cell transplantation.
|
Pediatr Blood Cancer
|
2010
|
1.04
|
|
72
|
Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease.
|
Biol Blood Marrow Transplant
|
2002
|
1.03
|
|
73
|
Effect of conditioning regimen intensity on acute myeloid leukemia outcomes after umbilical cord blood transplantation.
|
Biol Blood Marrow Transplant
|
2011
|
1.02
|
|
74
|
Promising progression-free survival for patients low and intermediate grade lymphoid malignancies after nonmyeloablative umbilical cord blood transplantation.
|
Biol Blood Marrow Transplant
|
2009
|
1.00
|
|
75
|
Diagnosis of myelodysplastic syndrome among a cohort of 119 patients with fanconi anemia: morphologic and cytogenetic characteristics.
|
Am J Clin Pathol
|
2010
|
0.99
|
|
76
|
Umbilical cord blood transplantation for myeloid malignancies.
|
Curr Opin Hematol
|
2007
|
0.98
|
|
77
|
Adoptive transfer of umbilical cord blood-derived regulatory T cells and early viral reactivation.
|
Biol Blood Marrow Transplant
|
2013
|
0.98
|
|
78
|
Early lymphocyte recovery and outcomes after umbilical cord blood transplantation (UCBT) for hematologic malignancies.
|
Biol Blood Marrow Transplant
|
2010
|
0.97
|
|
79
|
Homing defect of cultured human hematopoietic cells in the NOD/SCID mouse is mediated by Fas/CD95.
|
Exp Hematol
|
2003
|
0.97
|
|
80
|
Haematopoietic cell transplantation for acute leukaemia and advanced myelodysplastic syndrome in Fanconi anaemia.
|
Br J Haematol
|
2013
|
0.96
|
|
81
|
HLA-matched sibling hematopoietic stem cell transplantation for fanconi anemia: comparison of irradiation and nonirradiation containing conditioning regimens.
|
Biol Blood Marrow Transplant
|
2008
|
0.95
|
|
82
|
Umbilical cord blood transplantation: current state of the art.
|
Curr Opin Oncol
|
2002
|
0.94
|
|
83
|
Reduced intensity compared with high dose conditioning for allotransplantation in acute myeloid leukemia and myelodysplastic syndrome: a comparative clinical analysis.
|
Am J Hematol
|
2007
|
0.94
|
|
84
|
Allogeneic blood and bone marrow cells for the treatment of severe epidermolysis bullosa: repair of the extracellular matrix.
|
Lancet
|
2013
|
0.94
|
|
85
|
Effective treatment of alpha-mannosidosis by allogeneic hematopoietic stem cell transplantation.
|
J Pediatr
|
2004
|
0.93
|
|
86
|
Activated notch supports development of cytokine producing NK cells which are hyporesponsive and fail to acquire NK cell effector functions.
|
Biol Blood Marrow Transplant
|
2009
|
0.93
|
|
87
|
Unrelated cord blood transplantation in adult and pediatric acute lymphoblastic leukemia: effect of minimal residual disease on relapse and survival.
|
Biol Blood Marrow Transplant
|
2012
|
0.93
|
|
88
|
Analysis of risk factors influencing outcomes after cord blood transplantation in children with juvenile myelomonocytic leukemia: a EUROCORD, EBMT, EWOG-MDS, CIBMTR study.
|
Blood
|
2013
|
0.93
|
|
89
|
The effect of the composition of unrelated donor bone marrow and peripheral blood progenitor cell grafts on transplantation outcomes.
|
Biol Blood Marrow Transplant
|
2009
|
0.92
|
|
90
|
Keratinocytes from induced pluripotent stem cells in junctional epidermolysis bullosa.
|
J Invest Dermatol
|
2012
|
0.92
|
|
91
|
Umbilical cord blood transplantation: current practice and future innovations.
|
Crit Rev Oncol Hematol
|
2003
|
0.91
|
|
92
|
Cord blood transplantation for adults.
|
Vox Sang
|
2006
|
0.91
|
|
93
|
Comprehensive analysis of pathogenic deletion variants in Fanconi anemia genes.
|
Hum Mutat
|
2014
|
0.91
|
|
94
|
The Minnesota Molecular and Cellular Therapeutics Facility: a state-of-the-art biotherapeutics engineering laboratory.
|
Transfus Med Rev
|
2005
|
0.90
|
|
95
|
Human parainfluenza virus infection after hematopoietic stem cell transplantation: risk factors, management, mortality, and changes over time.
|
Biol Blood Marrow Transplant
|
2012
|
0.90
|
|
96
|
Consistency of the initial cell acquisition procedure is critical to the standardization of CD34+ cell enumeration by flow cytometry: results of a pairwise analysis of umbilical cord blood units and cryopreserved aliquots.
|
Transfusion
|
2008
|
0.90
|
|
97
|
Unrelated donor bone marrow transplantation for children with juvenile myelomonocytic leukaemia.
|
Br J Haematol
|
2002
|
0.90
|
|
98
|
A biologic Velcro patch.
|
N Engl J Med
|
2015
|
0.90
|
|
99
|
Advances in HLA: practical implications for selecting adult donors and cord blood units.
|
Biol Blood Marrow Transplant
|
2006
|
0.89
|
|
100
|
Impact of immune modulation with in vivo T-cell depletion and myleoablative total body irradiation conditioning on outcomes after unrelated donor transplantation for childhood acute lymphoblastic leukemia.
|
Blood
|
2012
|
0.88
|
|
101
|
Importance of donor ethnicity/race matching in unrelated adult and cord blood allogeneic hematopoietic cell transplant.
|
Leuk Lymphoma
|
2013
|
0.88
|
|
102
|
Using preimplantation genetic diagnosis to create a stem cell donor: issues, guidelines & limits.
|
J Law Med Ethics
|
2003
|
0.88
|
|
103
|
Production Assistance for Cellular Therapies (PACT): four-year experience from the United States National Heart, Lung, and Blood Institute (NHLBI) contract research program in cell and tissue therapies.
|
Transfusion
|
2008
|
0.88
|
|
104
|
Umbilical cord blood T cells express multiple natural cytotoxicity receptors after IL-15 stimulation, but only NKp30 is functional.
|
J Immunol
|
2008
|
0.87
|
|
105
|
Fanconi anemia gene editing by the CRISPR/Cas9 system.
|
Hum Gene Ther
|
2015
|
0.87
|
|
106
|
Suppressor function of umbilical cord blood-derived CD4+CD25+ T-regulatory cells exposed to graft-versus-host disease drugs.
|
Transplantation
|
2006
|
0.87
|
|
107
|
Rapid transport and infusion of hematopoietic cells is associated with improved outcome after myeloablative therapy and unrelated donor transplant.
|
Biol Blood Marrow Transplant
|
2009
|
0.87
|
|
108
|
Survival differences between adolescents/young adults and children with B precursor acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation.
|
Biol Blood Marrow Transplant
|
2012
|
0.86
|
|
109
|
Concise review: Transplantation of human hematopoietic cells for extracellular matrix protein deficiency in epidermolysis bullosa.
|
Stem Cells
|
2011
|
0.85
|
|
110
|
Allogeneic hematopoietic cell transplantation in children with relapsed acute lymphoblastic leukemia isolated to the central nervous system.
|
Biol Blood Marrow Transplant
|
2008
|
0.85
|
|
111
|
Complement fragment 3a priming of umbilical cord blood progenitors: safety profile.
|
Biol Blood Marrow Transplant
|
2013
|
0.84
|
|
112
|
Ex vivo expansion of umbilical cord blood hemopoietic stem and progenitor cells.
|
Exp Hematol
|
2004
|
0.84
|
|
113
|
Hematopoietic cell transplantation for congenital bone marrow failure.
|
Curr Opin Oncol
|
2005
|
0.84
|
|
114
|
Stem cell gene therapy for fanconi anemia: report from the 1st international Fanconi anemia gene therapy working group meeting.
|
Mol Ther
|
2011
|
0.84
|
|
115
|
Impact of bone marrow hematogones on umbilical cord blood transplantation outcomes in patients with acute myeloid leukemia.
|
Biol Blood Marrow Transplant
|
2011
|
0.83
|
|
116
|
Clinical-scale selection of anti-CD3/CD28-activated T cells after transduction with a retroviral vector expressing herpes simplex virus thymidine kinase and truncated nerve growth factor receptor.
|
Hum Gene Ther
|
2002
|
0.83
|
|
117
|
Management of severe epidermolysis bullosa by haematopoietic transplant: principles, perspectives and pitfalls.
|
Exp Dermatol
|
2012
|
0.82
|
|
118
|
Allogeneic hematopoietic cell transplantation in first remission abrogates poor outcomes associated with high-risk pediatric acute myeloid leukemia.
|
Biol Blood Marrow Transplant
|
2013
|
0.82
|
|
119
|
Radiotherapy of CD19 expressing Daudi tumors in nude mice with Yttrium-90-labeled anti-CD19 antibody.
|
Cancer Biother Radiopharm
|
2004
|
0.82
|
|
120
|
Formation of cyclophosphamide specific DNA adducts in hematological diseases.
|
Pediatr Blood Cancer
|
2011
|
0.81
|
|
121
|
An update from the United States National Heart, Lung, and Blood Institute-funded Production Assistance for Cellular Therapies (PACT) program: a decade of cell therapy.
|
Clin Transl Sci
|
2014
|
0.80
|
|
122
|
Leukodystrophy and gene therapy with a dimmer switch.
|
N Engl J Med
|
2011
|
0.80
|
|
123
|
Fatal hemorrhage from androgen-related hepatic adenoma after hematopoietic cell transplantation.
|
J Pediatr Hematol Oncol
|
2004
|
0.80
|
|
124
|
Current clinical management of Fanconi anemia.
|
Expert Rev Hematol
|
2012
|
0.80
|
|
125
|
Successful "in-flight" activation of natural killer cells during long-distance shipping.
|
Transfusion
|
2012
|
0.79
|
|
126
|
In vivo selection of antifolate-resistant transgenic hematopoietic stem cells in a murine bone marrow transplant model.
|
J Pharmacol Exp Ther
|
2002
|
0.79
|
|
127
|
A new route to the stem-cell niche.
|
Lancet Oncol
|
2008
|
0.79
|
|
128
|
Strategies for more rapid translation of cellular therapies for children: a US perspective.
|
Pediatrics
|
2013
|
0.79
|
|
129
|
Transplant outcomes in acute leukemia. I.
|
Semin Hematol
|
2010
|
0.78
|
|
130
|
UCB and atmospheric noise.
|
Blood
|
2010
|
0.78
|
|
131
|
Early hematopoietic stem cell transplant is associated with favorable outcomes in children with MDS.
|
Pediatr Blood Cancer
|
2012
|
0.78
|
|
132
|
More than 10 years after the first 'savior siblings': parental experiences surrounding preimplantation genetic diagnosis.
|
J Genet Couns
|
2013
|
0.78
|
|
133
|
First phase insulin release and glucose tolerance in children with Fanconi anemia after hematopoietic cell transplantation.
|
Pediatr Blood Cancer
|
2009
|
0.78
|
|
134
|
Recent developments in cell-based immune therapy for neuroblastoma.
|
J Neuroimmune Pharmacol
|
2007
|
0.78
|
|
135
|
Growth hormone treatment of patients with Fanconi anemia after hematopoietic cell transplantation.
|
Pediatr Blood Cancer
|
2013
|
0.78
|
|
136
|
One-unit versus two-unit cord-blood transplantation.
|
N Engl J Med
|
2015
|
0.77
|
|
137
|
A randomized trial of one versus two doses of influenza vaccine after allogeneic transplantation.
|
Biol Blood Marrow Transplant
|
2012
|
0.77
|
|
138
|
Umbilical cord transplantation: state of the art 2010.
|
Semin Hematol
|
2010
|
0.77
|
|
139
|
Cell therapy product administration and safety: data capture and analysis from the Production Assistance for Cellular Therapies (PACT) program.
|
Transfusion
|
2014
|
0.77
|
|
140
|
Myeloablative cord blood transplantation in adults with acute leukemia: comparison of two different transplant platforms.
|
Biol Blood Marrow Transplant
|
2013
|
0.76
|
|
141
|
Preimplantation testing to produce an HLA-matched donor infant.
|
JAMA
|
2004
|
0.76
|
|
142
|
Rapidly growing mycobacteria among pediatric hematopoietic cell transplant patients traced to the hospital water supply.
|
Pediatr Infect Dis J
|
2014
|
0.75
|
|
143
|
The epic race to immune reconstitution.
|
Biol Blood Marrow Transplant
|
2012
|
0.75
|
|
144
|
Donor-derived myelodysplastic syndrome and acute leukaemia after allogeneic haematopoietic stem cell transplantation: incidence, natural history and treatment response.
|
Br J Haematol
|
2014
|
0.75
|
|
145
|
Neoadjuvant chemotherapy with reduced-dose carboplatin and gemcitabine for non-small cell lung cancer in a patient with Fanconi anemia.
|
J Thorac Oncol
|
2008
|
0.75
|
|
146
|
Novel conditioning regimens and nonmyeloablative stem cell transplants.
|
Curr Opin Pediatr
|
2002
|
0.75
|